Table 2.
Relationships of the NKG2D gene polymorphisms with EULAR responses at 12 and 24 weeks of anti-TNF therapy.
| EULAR 12 Weeks | EULAR 24 Weeks | |||
|---|---|---|---|---|
| No Response (Number (%)) | Good/Moderate Response (Number (%)) | No Response (Number (%)) | Good/Moderate Response (Number (%)) | |
| NKG2D rs1049174 | (C|G: general population 51.3%|48.7%; Caucasian population: 68.4%|31.6%) * | |||
| C | 38 (82.6%) a | 342 (67.9%) a | 19 (67.9%) | 348 (68.0%) |
| G | 8 (17.4%) a | 162 (32.1%) a | 9 (32.1%) | 164 (32.0%) |
| CC | 17 (73.9%) b | 106 (41.2%) b | 6 (42.9%) | 113 (44.1%) |
| CG | 4 (17.4%) c | 130 (50.6%) c | 7 (50.0%) | 122 (47.7%) |
| GG | 2 (8.7%) | 21 (8.2%) | 1 (7.1%) | 21 (8.2%) |
| NKG2D rs1154831 | (A|C: general population 10.2%|89.8%; Caucasian population: 21.2%|78.8%) * | |||
| A | 11 (23.9%) | 90 (17.5%) | 6 (21.4%) | 90 (17.6%) |
| C | 35 (76.1%) | 424 (82.5%) | 22 (78.6%) | 422 (82.4%) |
| AA | 1 (4.3%) | 6 (2.3%) | 1 (7.1%) | 6 (2.3%) |
| AC | 9 (39.1%) | 78 (30.4%) | 4 (28.6%) | 78 (30.5%) |
| CC | 13 (56.5%) | 173 (67.3%) | 9 (64.3%) | 172 (67.2%) |
| NKG2D rs2255336 | (A|G: general population 23.8%|76.2%; Caucasian population: 18.6%|81.4%) * | |||
| A | 2 (4.3%) d | 114 (22.2%) d | 4 (14.3%) | 109 (21.3%) |
| G | 44 (95.7%) d | 400 (77.8%) d | 24 (85.7%) | 403 (78.7%) |
| AA | 0 (0.0%) | 12 (4.7%) | 0 (0.0%) | 12 (4.7%) |
| AG | 2 (8.7%) e | 90 (35.0%) e | 4 (28.6%) | 85 (33.2%) |
| GG | 21 (91.3%) f | 155 (60.3%) f | 10 (71.4%) | 159 (62.1%) |
a: p = 0.031, OR = 2.39, 95%CI (1.07, 6.05); b: CC vs. CG + GG, p = 0.004, OR = 4.02, 95%CI (1.45, 12.87); c: CG vs. CC + GG, p = 0.002, OR = 0.21, 95%CI (0.05, 0.65); d: p = 0.002, OR = 6.26, 95%CI (1.59, 54.05); e: AG vs. AA + GG, p = 0.010, OR = 0.18, 95%CI (0.02, 0.75); f: GG vs. AG + AA, p = 0.003, OR = 6.88, 95%CI (1.62, 61.80); *: source: The 1000 Genomes Project (phase 3) (http://www.internationalgenome.org/); OR: odds ratio; 95%CI: 95% confidence interval; EULAR: European League Against Rheumatism response criteria; percentages calculated in regard to a total number of patients in a given responders group.